

Eradication of *Helicobacter pylori* Infection

Elizabeth A. Marcus^{1,4} · George Sachs^{2,3,4} · David R. Scott^{2,4}

Published online: 13 May 2016
© Springer Science+Business Media New York 2016

Abstract *Helicobacter pylori* infects about 50 % of the world's population, causing at a minimum chronic gastritis. A subset of infected patients will ultimately develop gastric or duodenal ulcer disease, gastric adenocarcinoma, or MALT (mucosa-associated lymphoid tissue) lymphoma. Eradication of *H. pylori* requires complex regimens that include acid suppression and multiple antibiotics. The efficacy of treatment using what were once considered standard regimens have declined in recent years, mainly due to widespread development of antibiotic resistance. Addition of bismuth to standard triple therapy regimens, use of alternate antibiotics, or development of alternative regimens using known therapies in novel combinations have improved treatment efficacy in specific populations, but overall success of eradication remains less than ideal. Novel regimens under investigation either in vivo or in vitro, involving increased acid suppression ideally with fewer antibiotics or development of non-antibiotic treatment targets, show promise for future therapy.

Keywords *Helicobacter pylori* · Gastric acid · Antibiotic resistance · Eradication

This article is part of the Topical Collection on *Stomach and Duodenum*

✉ Elizabeth A. Marcus
emarcus@mednet.ucla.edu

- ¹ Department of Pediatrics, DGSOM at UCLA, Los Angeles, CA, USA
- ² Department of Physiology, DGSOM at UCLA, Los Angeles, CA, USA
- ³ Department of Medicine, DGSOM at UCLA, Los Angeles, CA, USA
- ⁴ VA GLAHS, 11301 Wilshire Blvd. Bldg 113 Rm 324, Los Angeles, CA 90073, USA

Introduction

Helicobacter pylori, a Gram-negative bacterium that infects the normal acid secreting human stomach, was first connected to the development of ulcer disease in 1984 [1]. The bacteria infects about 50 % of the world's population, leading to gastritis in 100 % of those infected, and a fraction of those individuals will ultimately develop gastric or duodenal ulcer disease, gastric adenocarcinoma, or MALT (mucosa-associated lymphoid tissue) lymphoma [2–6]. *H. pylori* was designated as a class one or definite carcinogen by the World Health Organization on the basis of the established connection with gastric cancer [7, 8]. The worldwide burden of gastric cancer is high. Gastric cancer is the fourth most common cancer and the second most common cause of cancer death [9]. Eradication of *H. pylori* infection leads to improvement or resolution of associated pathology, underscoring the importance of effective therapy. Successful treatment of *H. pylori* leads to ulcer healing rates of >90 % and is effective in preventing recurrence of bleeding [10–12]. Low-grade MALT lymphoma, in the absence of genetic translocations, can be treated by eradication of *H. pylori* [13–15]. Eradication of *H. pylori* is proven to be beneficial for prevention of gastric cancer [16] and leads to eventual regression of acute and chronic inflammation [17]. Success rates of standard therapy regimens, typically including acid suppression and multiple antibiotics, have fallen below the acceptable level of 80 % in many parts of the world [18]. The reason for the decline in treatment success appears to be multifactorial, involving issues such as expanding antibiotic resistance, patient compliance, and host and bacterial factors that alter the efficacy of treatment [19]. Antibiotic resistance is generally believed to be the major contributor to treatment failure, underscoring the importance of understanding why current regimens fail and identifying new treatment regimens.

Scientific Basis for Standard Therapy

H. pylori colonizes an acidic niche in the human stomach. It was originally believed that, even though the gastric lumen has a median pH near 1.4 in normal acid secreting humans [20], the actual site of infection was closer to neutral pH due to a pH gradient through the mucus layer [21]. These studies were done with glass-tipped microelectrodes, and may have been hindered by technique due to difficulty in diffusion of protons through the electrodes. Several studies in the interim have provided evidence for a more acidic environment at the site of infection. Later work using microelectrodes in mice have suggested that the presence of *H. pylori* removes any potential barriers to proton diffusion [22]. Fluorescent dye studies completed in externalized stomachs of anesthetized mice also suggested an acidic pH at the gastric surface, regardless of the presence of a mucus layer [23]. The gastric surface pH is a combination of regulation of acid and alkali secretion to a specific set point rather than a result of trapping of buffers or protons under the mucus layer [23]. Transcriptome studies done in vitro at acidic and neutral pH and in bacteria collected from infected gerbils demonstrated that genes regulated by acidic pH in vitro show similar changes in expression in the gerbil stomach, again suggesting acidic pH at the site of infection [24]. *H. pylori* typically infects the gastric antrum but the infection predominates in the gastric body with acid suppressive therapy [25–28], providing additional evidence that the bacteria are adapted to live in a very specific environment with regard to local pH.

In apparent conflict with the need for *H. pylori* to inhabit an acidic niche, the bacteria are bioenergetically neutralophiles, meaning they are able to survive between pH 4–8 and grow between pH 6–8. The bioenergetic profile has been confirmed using studies measuring membrane potential [29]. The bacteria have adapted to survive in their very specific niche through a mechanism termed acid acclimation or the ability to maintain periplasmic pH near neutral in an acidic environment [30]. This is distinct from the acid resistance mechanisms seen in other bacteria that merely have to survive passage through the stomach and are designed to moderately elevate cytoplasmic pH [31]. Acid acclimation in *H. pylori* is centered on a neutral pH optimum cytoplasmic urease enzyme, which hydrolyzes urea into carbonic acid and ammonia, and an inner membrane localized, proton-gated urea channel, UreI [30, 32, 33]. A periplasmic-localized α -carbonic anhydrase enzyme contributes to periplasmic buffering by catalyzing the conversion of carbon dioxide produced by urease into bicarbonate [30]. The bacteria are able to sense environmental pH via the use of two-component signaling systems, which are able to stimulate protein trafficking, facilitating periplasmic alkalization, and increase transcription of acid acclimation genes [34].

Acid acclimation and *H. pylori* bioenergetics are critical to successful treatment protocols. Available regimens

are classically based on acid suppression and multiple antibiotics. The bacteria are uniquely adapted to survive in the acidic environment of the stomach, but based on their status as neutralophiles, a smaller fraction of the bacteria will actually be dividing or growing in acid as compared to more neutral pH. This is demonstrated in transcriptome studies, where genes involved in cell division and cell wall synthesis are up-regulated at neutral pH [35]. Most antibiotics used to treat *H. pylori* are dependent on bacterial growth and will work on bacteria that are actively dividing, which will occur more readily with adequate acid suppression [35]. *H. pylori* that are not dividing at the time of antibiotic administration will not be killed by the antibiotics, leaving a small population of viable bacteria that can restore colonization of the stomach once the antibiotics are stopped. This is considered a form of phenotypic resistance, where treatment can fail despite appropriate antibiotic coverage [36, 37••]. Medications currently available for acid blockade, at recommended doses, will not consistently achieve the sustained pH change required to mimic the bactericidal effect seen in in vitro studies [35, 38].

Standard Triple and Bismuth-Containing Quadruple Therapy

Standard first line treatment for *H. pylori* infection has classically been triple therapy with BID PPI, clarithromycin, and either metronidazole or amoxicillin. Clarithromycin is bacteriostatic and inhibits protein synthesis by binding to the 50S ribosomal subunit. Metronidazole is bactericidal and works via activation within the bacteria, leading to production of toxic metabolites. Amoxicillin is bactericidal and inhibits synthesis of bacterial cell walls. Efficacy is equivalent when using either amoxicillin or metronidazole [39]. Use of high dose BID PPI will increase cure rates with standard therapy regimens by 6–10 % [40]. Treatment duration is important as well, as a 14-day dosing schedule increased efficacy of eradication by 5–6 % when compared to a 7-day regimen, without causing a significant difference in side effect profile [41–43]. Standard triple therapy was initially acceptably efficacious, with treatment success ranging from >80 to >90 % in the early 1990s [44, 45]. Success of this regimen has declined globally over time, dropping to unacceptable levels in many regions [19•, 46]. The main identified reason for treatment failure with standard triple therapy is resistance to clarithromycin, with compliance, bacterial load, and strain differences also identified as potential contributing factors [47]. Clarithromycin resistance is mediated either by point mutations that prevent antibiotic binding to the ribosome or via development of antibiotic efflux channels [48, 49]. When deciding to use standard triple therapy, it is important to review a patient's prior antibiotic use

since past exposure to any of the macrolide antibiotics may predict clarithromycin resistance [50]. Current guidelines suggest that standard triple therapy should not be used if regional levels of clarithromycin resistance are >15–20 % [47]. Metronidazole resistance, mediated by mutations leading to inactivation of the bacterial enzymes needed to activate the antibiotic, is also fairly prevalent worldwide [51, 52]. Like clarithromycin, prior exposure to metronidazole is an important factor in treatment success [50]. Two important differences exist when comparing metronidazole resistance to clarithromycin resistance. Metronidazole resistance has remained more stable worldwide while clarithromycin resistance has increased [53]. Metronidazole resistance can also be overcome by increasing the antibiotic dose [54, 55]. Amoxicillin resistance, mediated by a variety of different mechanisms including mutations in penicillin-binding proteins, decreased permeability for the antibiotic, or development of efflux pumps, is extremely rare in *H. pylori* [47, 56].

In the case of failed standard triple therapy, or as first line therapy in regions of high clarithromycin resistance, bismuth-containing quadruple regimens can be considered [47]. These regimens consist of BID PPI, bismuth, and two antibiotics [47], ideally for 14 days, and have overall improved efficacy compared with triple therapy in regions with higher levels of clarithromycin or metronidazole resistance [57]. Several recent studies have confirmed efficacy of adding bismuth to clarithromycin or levofloxacin-containing regimens, even in the setting of either high levels of resistance or known resistance based on susceptibility testing. Cure rates across these studies were either >90 % for 14 day regimens or demonstrated improvement from region-based expected eradication levels of 30–40 % up to 70–85 % [55, 58–61]. Resistance of *H. pylori* to bismuth has not been reported [62–64]. The mechanism of action of bismuth on *H. pylori* is not definitively known. Bismuth preparations, on rare occasions, have been noted to have some independent bactericidal action against *H. pylori* [65–67]. Bismuth has mainly a local effect on *H. pylori*, as absorption is not required for efficacy [68]. Older in vitro studies suggest that bismuth may work against *H. pylori* via deposition both on the surface of the bacteria and in the region between the cell wall and the cytoplasmic membrane, disrupting critical bacterial functions [69, 70]. More recent in vitro work suggests that bismuth impedes proton entry into the bacteria, allowing for upregulation of growth-dependent genes and increased efficacy of growth-dependent antibiotics [71]. The downsides to bismuth-containing quadruple therapy include increased complexity of the regimens and increased side effect potential, which may interfere with compliance. Having a non-antibiotic component as part of a widely used regimen has the long-term benefit of durability of response, without the concern for development of resistance over time.

Alternative Antibiotics

Rising resistance rates and antibiotic availability in different regions may necessitate the use of different antibiotics beyond the standard therapy protocols. The most common antibiotic used in second line or salvage therapies is levofloxacin. Levofloxacin works by inhibiting bacterial topoisomerase II [72]. In most cases of failed first line therapy, it is assumed that antibiotic resistance may have played a role, and antibiotics should be altered [37••]. Triple therapy with levofloxacin replacing clarithromycin, given that amoxicillin resistance is extremely rare, is a recommended second line regimen [47]. Levofloxacin can also be substituted for clarithromycin in a variety of alternative regimens based on local resistance patterns. Levofloxacin and other fluoroquinolones are widely used for a variety of bacterial infections and levofloxacin should not be considered for treatment of *H. pylori* in patients with a history of chronic infections treated with this class of antibiotics [47]. Due to its widespread and growing use worldwide, the incidence of levofloxacin-resistant *H. pylori* is growing rapidly [37••]. Resistance is typically caused by point mutations in the *H. pylori* DNA gyrase [73, 74]. Fourteen-day triple therapy with levofloxacin will not reach the target of 90 % success if the local resistance rate is over 12 %, and addition of bismuth requires a local resistance rate of <25 % [60, 75]. Overall, levofloxacin can be considered as a reasonable second line regimen if local clarithromycin resistance exceeds 15–20 % and levofloxacin resistance is less than 10 %, or as part of an empiric salvage regimen in areas of low fluoroquinolone resistance [47, 76••].

Tetracycline is bactericidal and works by inhibiting protein synthesis. Tetracycline resistance, mediated either by efflux proteins or ribosomal protection proteins [77], is less prevalent worldwide than resistance to clarithromycin, metronidazole, or levofloxacin. In patients in Taiwan receiving a second course of treatment for a prior failure, addition of tetracycline to PPI, bismuth, and amoxicillin was more effective than addition of metronidazole [78]. Use of tetracycline has become more prominent since the introduction of Pylera®, a combined pill containing bismuth, tetracycline, and metronidazole that can be taken four times daily in combination with a twice daily PPI. The benefit of this combined pill formulation is the likelihood of improved patient compliance. Use of Pylera® resulted in eradication rates of 80–93 % in a series of studies conducted in populations who were either treatment naïve or had failed one treatment course [79–82]. A more recent study looked at effectiveness of this regimen in patients with known resistance to metronidazole, clarithromycin, and levofloxacin or who had failed multiple prior treatment courses, and found eradication rates of 83 % (intention to treat) and 87 % (per-protocol) [83]. These numbers are encouraging especially in the setting of known metronidazole resistance and in a difficult to treat population. Tetracycline should be considered as a

part of second line or salvage regimens, typically as a part of bismuth-containing quadruple therapy regimens, especially in areas where antibiotic resistance is of high concern.

Rifabutin is a bactericidal antibiotic that works by blocking bacterial RNA polymerase. Resistance of *H. pylori* to rifabutin is very low, about 1 % overall [37••], typically mediated by genomic point mutations [84, 85]. The most commonly used rifabutin-containing regimen is in combination with a PPI and amoxicillin for 14 days, with greater efficacy (over 90 %) seen when using high doses of both the PPI and amoxicillin [86, 87]. The mean success rate of regimens containing rifabutin is 73 % according to a comprehensive review completed in 2012 [88]. Rifabutin should only be used as a salvage therapy due to the potential for creating resistance to mycobacteria and the risk of side effects such as myelotoxicity [88].

Alternative Regimens

Several alternative treatment regimens designed to overcome the problems faced with standard protocols have been developed and extensively tested. Sequential therapy is a 10-day regimen which begins with 5 days of BID PPI and amoxicillin (or levofloxacin if penicillin-allergic), with discontinuation of amoxicillin and initiation of clarithromycin and metronidazole for treatment days 6–10 [47, 89, 90]. This regimen can be extended to 14 days, with reported superiority over standard triple therapy for 14 days in a recent multi-center study completed in Taiwan [91]. The rationale for this regimen is that the amoxicillin is used to help overcome clarithromycin resistance. By disrupting bacterial cell walls, amoxicillin interferes with the activation of clarithromycin efflux channels in resistant organisms [49, 89]. Sequential therapy is considered first line treatment in regions of high clarithromycin resistance where bismuth is not readily available [47]. In one analysis, sequential therapy was shown to be effective 75 % of the time in clarithromycin-resistant strains [92]. A recent meta-analysis demonstrated that 14 day sequential therapy was a more effective first line regimen than 14 day triple therapy [93]. The downsides to sequential therapy include challenges with patient compliance with a complex regimen and the potential to either foster resistance to multiple antibiotics or limit salvage options in the event of treatment failure [76••, 94].

Concomitant therapy, or non-bismuth quadruple therapy, includes a PPI and three antibiotics, typically clarithromycin, amoxicillin, and metronidazole, ideally for 14 days. This regimen is superior to standard triple therapy as demonstrated in a recent randomized controlled trial and multiple meta-analyses [95–97]. The appeal of this regimen as compared to sequential therapy is that there is no need to change antibiotics half way through the treatment course, which is easier for patients and should boost compliance [37••]. This regimen shows reasonable success in areas of high clarithromycin or metronidazole

resistance, but efficacy drops when the prevalence of strains resistant to both antibiotics is greater than 15 %, such as Latin America, Turkey, or Korea [98].

Hybrid therapy is a combination of sequential and concomitant therapy, starting with 7 days of PPI and amoxicillin, followed by addition of clarithromycin and metronidazole (four-drug regimen) for the final 7 days [99]. Reverse hybrid therapy involves all four drugs for the first 7 days, followed by amoxicillin and PPI for the final 7 days [100]. Since medications are added during treatment rather than changed, this regimen should be simpler than sequential therapy. There is less overall antibiotic exposure than with concomitant therapy, potentially making this regimen more attractive in regions where it is effective. Similar to concomitant therapy, effectiveness will be decreased in regions with high prevalence of strains with combined metronidazole and clarithromycin resistance [98]. Success rates, as expected, are region-dependent [37••]. A meta-analysis completed in early 2015 showed overall similar efficacy when comparing hybrid, concomitant, and sequential therapies [101]. A meta-analysis completed later in 2015 including eight studies and 2516 enrolled subjects again showed hybrid therapy was similar to sequential therapy and to concomitant therapy in terms of success rate and concluded that hybrid therapy was overall effective and well-tolerated [100]. Based on the available literature, the overall decision to choose an alternative regimen should be based on local resistance patterns, prior antibiotic exposures (relating to *H. pylori* treatment or other infections), and expected patient compliance.

The Future of Therapy

The two most significant barriers to effective treatment for *H. pylori* infection are antibiotic resistance and patient compliance. With this in mind, the future of treatment needs to be focused on either simpler regimens, use of antibiotics with less chance of development of resistance, or development of non-antibiotic regimens targeting the ability of the bacteria to survive in the stomach. Both primary and secondary resistance of *H. pylori* to amoxicillin are very rare [102–104], making this antibiotic a viable candidate for study of dual therapy regimens with PPIs. Dual therapy with PPI and amoxicillin has been studied in different formats for over 20 years, but consistency in results has not been established, and fine tuning is likely required to establish this regimen as a standard treatment protocol. A meta-analysis completed in 1994 suggested a >80 % eradication rate with omeprazole 20 mg BID and amoxicillin >2 g total daily and hinted at the importance of acid suppression in these regimens. Success rates of 30–50 % were seen with similar dual regimens in 1995 and 1998 [105, 106], but most significantly, the 1998 study highlighted the importance of profound acid suppression. The only significant

factors in successful eradication with PPI-amoxicillin dual therapy were percent time > pH 4 and continuous time > pH 6 [106]. More recently, the recognition of P450 CYP 2C19 polymorphisms that affect the metabolism of PPIs has presented a possible mechanism of treatment failure. Poor metabolizers, who are able to maintain a higher intra-gastric pH on PPI therapy, have a better response to dual therapy regardless of PPI dose, but genotype is less of a factor as PPI doses are increased [107]. Amoxicillin-dosing frequency is an important factor as well. Amoxicillin, unlike many other antibiotics used in *H. pylori* treatment regimens, is time-dependent, not concentration-dependent, so time above MIC is an important factor in efficacy [108, 109]. A regimen of four times daily rabeprazole (20 mg) and four times daily amoxicillin (750 mg) for 14 days was recently shown to be superior to standard treatment regimens in a Taiwanese population [110]. Optimization of acid suppression may ultimately lead to a standard dual therapy regimen that is effective worldwide.

High dose PPI use in dual or standard therapy regimens may ultimately be replaced by more potent acid suppressive agents. The potassium competitive inhibitor of the gastric H, K-ATPase, vonoprazan, is coming into clinical use in Asia and has the benefit of a more rapid and sustained acid inhibitory effect regardless of CYP 2C19 genotype [111]. Use of vonoprazan in place of PPIs has shown early promise in recent studies of Japanese populations, with an eradication rate of 70.2 % using vonoprazan, amoxicillin, and clarithromycin as second line therapy in patients who have failed first line treatment with rabeprazole, amoxicillin, and clarithromycin and a 92.7 % success rate of first line therapy with vonoprazan, amoxicillin, and clarithromycin [112, 113].

Non-antibiotic regimens would be the ideal for future management of *H. pylori* infection as this would avoid the concerning issue of worsening widespread antibiotic resistance. Potential treatments would target the components of acid acclimation that allow the bacteria to colonize the stomach, such as the urea channel, the two-component signaling systems that detect medium pH, or the carbonic anhydrase enzymes. Inhibition or gene knockout of α -carbonic anhydrase has shown promise in vitro as a potential treatment target in the presence of acid [30]. Acetazolamide, a carbonic anhydrase inhibitor used clinically for altitude sickness or alkalosis, were shown to have benefit for ulcer healing prior to the discovery of *H. pylori* [114]. One pilot study done in humans, looking at efficacy of acetazolamide in eradication of *H. pylori*, was unsuccessful, but the dose and duration of treatment were likely inappropriate [115, 116]. Use of non-antibiotic targeted treatments of this nature would require attention to obstacles not only of dose and duration but also to ability to reach bacteria in the gastric lumen.

Conclusions

H. pylori is a highly prevalent global pathogen that causes chronic inflammation in all who are infected, carries a risk of advanced disease including ulcers and gastric cancer, and faces growing challenges with treatment efficacy. Standard triple therapy with proton pump inhibitor, clarithromycin, and either amoxicillin or metronidazole is no longer sufficiently efficacious in many parts of the world due to antibiotic resistance patterns. New regimens with bismuth, different antibiotics, or different combinations of standard antibiotics have shown variable promise. As antibiotic use for a variety of different infections increases, the problems inherent with the use of primarily antibiotic-based regimens for *H. pylori* will only increase. Use of enhanced acid suppression to improve efficacy of growth-dependent antibiotics, preference for regimens including antibiotics with lower risk for resistance, and continued focus on the search for non-antibiotic treatment targets will shape the future of treatment for *H. pylori*. Choice of regimens for patients at the present time should be based on knowledge of local resistance patterns and antibiotic use, patient history, and accommodations to facilitate optimal compliance.

Funding The authors are supported by K08DK100661 (EAM), UCLA CDI (EAM), USVA 2I01BX001006 (GS), R01DK105156-01 (GS).

Compliance with Ethical Standards

Conflict of Interest The authors declare that they have no conflicts of interest.

Human and Animal Rights and Informed Consent This article does not contain any studies with human or animal subjects performed by any of the authors.

References

Papers of particular interest, published recently, have been highlighted as:

- Of importance
- Of major importance

1. Marshall BJ, Warren JR. Unidentified curved bacilli in the stomach of patients with gastritis and peptic ulceration. *Lancet*. 1984;1(8390):1311–5.
2. Blaser MJ. Hypotheses on the pathogenesis and natural history of *Helicobacter pylori*-induced inflammation. *Gastroenterology*. 1992;102(2):720–7.
3. Nomura A, Stemmermann GN, Chyou PH, Kato I, Perez-Perez GI, Blaser MJ. *Helicobacter pylori* infection and gastric carcinoma among Japanese Americans in Hawaii. *N Engl J Med*. 1991;325(16):1132–6.

4. Parsonnet J. Gastric adenocarcinoma and *Helicobacter pylori* infection. *Western J Med.* 1994;161(1):60.
5. Parsonnet J, Friedman GD, Vandersteen DP, Chang Y, Vogelman JH, Orentreich N, et al. *Helicobacter pylori* infection and the risk of gastric carcinoma. *N Engl J Med.* 1991;325(16):1127–31.
6. Suerbaum S, Michetti P. *Helicobacter pylori* infection. *N Engl J Med.* 2002;347(15):1175–86.
7. Infection with *Helicobacter pylori* In: Cancer IAFRo, editor. IARC monographs on the evaluation of the carcinogenic risk to humans-Schistosomes, liver flukes, and *Helicobacter pylori*. Lyon, France 1994. p. 177–240.
8. Bosman FT, Carneiro F, Hruban RH, Theise ND. WHO: classification of tumors of the digestive system. 4th ed. Geneva: IARC Press; 2010.
9. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. *Int J Cancer.* 2008;127(12):2893–917.
10. Ford AC, Delaney BC, Forman D, Moayyedi P. Eradication therapy for peptic ulcer disease in *Helicobacter pylori* positive patients. *Cochrane database of systematic reviews (Online).* 2006(2):CD003840.
11. Gisbert JP, Khorrani S, Carballo F, Calvet X, Gene E, Dominguez-Munoz JE. *H. pylori* eradication therapy vs. antisecretory non-eradication therapy (with or without long-term maintenance antisecretory therapy) for the prevention of recurrent bleeding from peptic ulcer. *Cochrane database of systematic reviews (Online).* 2003(4):CD004062.
12. Leodolter A, Kulig M, Brasch H, Meyer-Sabellek W, Willich SN, Malfertheiner P. A meta-analysis comparing eradication, healing and relapse rates in patients with *Helicobacter pylori*-associated gastric or duodenal ulcer. *Aliment Pharmacol Ther.* 2001;15(12):1949–58.
13. Chen LT, Lin JT, Tai JJ, Chen GH, Yeh HZ, Yang SS, et al. Long-term results of anti-*Helicobacter pylori* therapy in early-stage gastric high-grade transformed MALT lymphoma. *J Natl Cancer Inst.* 2005;97(18):1345–53.
14. Stathis A, Chini C, Bertoni F, Proserpio I, Capella C, Mazzucchelli L, et al. Long-term outcome following *Helicobacter pylori* eradication in a retrospective study of 105 patients with localized gastric marginal zone B-cell lymphoma of MALT type. *Ann Oncol.* 2009;20(6):1086–93.
15. Wotherspoon AC, Doglioni C, Diss TC, Pan L, Moschini A, de Boni M, et al. Regression of primary low-grade B-cell gastric lymphoma of mucosa-associated lymphoid tissue type after eradication of *Helicobacter pylori*. *Lancet.* 1993;342(8871):575–7.
16. Wong BC, Lam SK, Wong WM, Chen JS, Zheng TT, Feng RE, et al. *Helicobacter pylori* eradication to prevent gastric cancer in a high-risk region of China: a randomized controlled trial. *JAMA.* 2004;291(2):187–94.
17. Tulassay Z, Stolte M, Engstrand L, Butruk E, Malfertheiner P, Dite P, et al. Twelve-month endoscopic and histological analysis following proton-pump inhibitor-based triple therapy in *Helicobacter pylori*-positive patients with gastric ulcers. *Scand J Gastroenterol.* 2010;45(9):1048–58.
18. Graham DY, Lu H, Yamaoka Y. A report card to grade *Helicobacter pylori* therapy. *Helicobacter.* 2007;12(4):275–8. doi:10.1111/j.1523-5378.2007.00518.x.
19. Kim SY, Choi DJ, Chung JW. Antibiotic treatment for *Helicobacter pylori*: is the end coming? *World J Gastrointest Pharmacol Ther.* 2015;6(4):183–98. doi:10.4292/wjgpt.v6.i4.183. **Provides a helpful overview of worldwide antibiotic resistance patterns.**
20. Teyssen S, Chari ST, Scheid J, Singer MV. Effect of repeated boluses of intravenous omeprazole and primed infusions of ranitidine on 24-hour intragastric pH in healthy human subjects. *Dig Dis Sci.* 1995;40(2):247–55.
21. Code CF. Defense mechanisms of the gastric mucosa. *Scand J Gastroenterol Suppl.* 1981;67:201–4.
22. Henriksnas J, Phillipson M, Storm M, Engstrand L, Soleimani M, Holm L. Impaired mucus-bicarbonate barrier in *Helicobacter pylori*-infected mice. *Am J Physiol.* 2006;291(3):G396–403.
23. Baumgartner HK, Montrose MH. Regulated alkali secretion acts in tandem with unstirred layers to regulate mouse gastric surface pH. *Gastroenterology.* 2004;126(3):774–83.
24. Scott DR, Marcus EA, Wen Y, Oh J, Sachs G. Gene expression in vivo shows that *Helicobacter pylori* colonizes an acidic niche on the gastric surface. *Proc Natl Acad Sci U S A.* 2007;104(17):7235–40.
25. Larkin CJ, Watson RGP, Sloan JM, Stevenson M, Ardill JE, Buchanan D. Distribution of atrophy in *Helicobacter pylori*-infected subjects taking proton pump inhibitors. *Scand J Gastroenterol.* 2000;35(6):578–82.
26. Lee A, Dixon MF, Danon SJ, Kuipers E, Megraud F, Larsson H, et al. Local acid production and *Helicobacter pylori*: a unifying hypothesis of gastroduodenal disease. *Eur J Gastroenterol Hepatol.* 1995;7(5):461–5.
27. Logan RP, Walker MM, Misiewicz JJ, Gummett PA, Karim QN, Baron JH. Changes in the intragastric distribution of *Helicobacter pylori* during treatment with omeprazole. *Gut.* 1995;36(1):12–6.
28. Mollenhauer-Rektorschek M, Hanauer G, Sachs G, Melchers K. Expression of UreI is required for intragastric transit and colonization of gerbil gastric mucosa by *Helicobacter pylori*. *Res Microbiol.* 2002;153(10):659–66.
29. Meyer-Rosberg K, Scott DR, Rex D, Melchers K, Sachs G. The effect of environmental pH on the proton motive force of *Helicobacter pylori*. *Gastroenterology.* 1996;111(4):886–900.
30. Marcus EA, Moshfegh AP, Sachs G, Scott DR. The periplasmic alpha-carbonic anhydrase activity of *Helicobacter pylori* is essential for acid acclimation. *J Bacteriol.* 2005;187(2):729–38.
31. Ma Z, Gong S, Richard H, Tucker DL, Conway T, Foster JW. GadE (YhiE) activates glutamate decarboxylase-dependent acid resistance in *Escherichia coli* K-12. *Mol Microbiol.* 2003;49(5):1309–20.
32. Scott DR, Marcus EA, Weeks DL, Lee A, Melchers K, Sachs G. Expression of the *Helicobacter pylori ureI* gene is required for acidic pH activation of cytoplasmic urease. *Infect Immun.* 2000;68(2):470–7.
33. Weeks DL, Eskandari S, Scott DR, Sachs G. A H⁺-gated urea channel: the link between *Helicobacter pylori* urease and gastric colonization. *Sci (New York, NY).* 2000;287(5452):482–5.
34. Marcus EA, Sachs G, Wen Y, Feng J, Scott DR. Role of the *Helicobacter pylori* sensor kinase ArsS in protein trafficking and acid acclimation. *J Bacteriol.* 2012;194(20):5545–51.
35. Marcus EA, Inatomi N, Nagami GT, Sachs G, Scott DR. The effects of varying acidity on *Helicobacter pylori* growth and the bactericidal efficacy of ampicillin. *Aliment Pharmacol Ther.* 2012;36(10):972–9.
36. Graham DY, Fischbach L. *Helicobacter pylori* treatment in the era of increasing antibiotic resistance. *Gut.* 2010;59(8):1143–53.
37. Molina-Infante J, Shiotani A. Practical aspects in choosing a *Helicobacter pylori* therapy. *Gastroenterol Clin N Am.* 2015;44(3):519–35. doi:10.1016/j.gtc.2015.05.004. **A clearly written and rational guide explaining why different treatment regimens may be appropriate or less ideal for *H. pylori* infection in specific circumstances.**
38. Sugimoto M, Shirai N, Nishino M, Kodaira C, Uotani T, Yamada M, et al. Rabeprazole 10 mg q.d.s. decreases 24-h intragastric acidity significantly more than rabeprazole 20 mg b.d. or 40 mg o.m., overcoming CYP2C19 genotype. *Aliment Pharmacol Ther.* 2012;36(7):627–34. doi:10.1111/apt.12014.
39. Gisbert JP, Gonzalez L, Calvet X, Garcia N, Lopez T, Roque M, et al. Proton pump inhibitor, clarithromycin and either amoxicillin

- or nitroimidazole: a meta-analysis of eradication of *Helicobacter pylori*. *Aliment Pharmacol Ther.* 2000;14(10):1319–28.
40. Villoria A. Acid-related diseases: are higher doses of proton pump inhibitors more effective in the treatment of *Helicobacter pylori* infection? *Gastroenterol Hepatol.* 2008;31(8):546–7.
 41. Calvet X, Garcia N, Lopez T, Gisbert JP, Gene E, Roque M. A meta-analysis of short versus long therapy with a proton pump inhibitor, clarithromycin and either metronidazole or amoxicillin for treating *Helicobacter pylori* infection. *Aliment Pharmacol Ther.* 2000;14(5):603–9.
 42. Ford A, Moayyedi P. How can the current strategies for *Helicobacter pylori* eradication therapy be improved? *Can J Gastroenterol.* 2003;17(Suppl B):36B–40B.
 43. Fuccio L, Minardi ME, Zagari RM, Grilli D, Magrini N, Bazzoli F. Meta-analysis: duration of first-line proton-pump inhibitor based triple therapy for *Helicobacter pylori* eradication. *Ann Intern Med.* 2007;147(8):553–62.
 44. Lind T, van Zanten VS, Unge P, Spiller R, Bayerdorffer E, O'Morain C, et al. Eradication of *Helicobacter pylori* using one-week triple therapies combining omeprazole with two antimicrobials: the MACH I Study. *Helicobacter.* 1996;1(3):138–44.
 45. Malfertheiner P, Megraud F, O'Morain C, Bell D, Bianchi Porro G, Deltenre M, et al. Current European concepts in the management of *Helicobacter pylori* infection—the Maastricht Consensus report. The European *Helicobacter Pylori* study group (EHPSG). *Eur J Gastroenterol Hepatol.* 1997;9(1):1–2.
 46. Khalifa MM, Sharaf RR, Aziz RK. *Helicobacter pylori*: a poor man's gut pathogen? *Gut Pathog.* 2010;2(1):2. doi:10.1186/1757-4749-2-2.
 47. Malfertheiner P, Megraud F, O' Morain CA, Atherton J, Axon AT, Bazzoli F, et al. Management of *Helicobacter pylori* infection—the Maastricht IV/Florence consensus report. *Gut.* 2012;61(5):646–64.
 48. Megraud F. *H. pylori* antibiotic resistance: prevalence, importance, and advances in testing. *Gut.* 2004;53(9):1374–84. doi:10.1136/gut.2003.022111.
 49. Webber MA, Piddock LJ. The importance of efflux pumps in bacterial antibiotic resistance. *J Antimicrob Chemother.* 2003;51(1):9–11.
 50. McMahon BJ, Hennessy TW, Bensler JM, Bruden DL, Parkinson AJ, Morris JM, et al. The relationship among previous antimicrobial use, antimicrobial resistance, and treatment outcomes for *Helicobacter pylori* infections. *Ann Intern Med.* 2003;139(6):463–9.
 51. Goodwin A, Kersulyte D, Sisson G, van Zanten VSJ, Berg DE, Hoffman PS. Metronidazole resistance in *Helicobacter pylori* is due to null mutations in a gene (*rdxA*) that encodes an oxygen-insensitive NADPH nitroreductase. *Mol Microbiol.* 1998;28(2):383–93.
 52. Jenks PJ, Edwards DI. Metronidazole resistance in *Helicobacter pylori*. *Int J Antimicrob Agents.* 2002;19(1):1–7.
 53. Chey WD, Wong BC. Practice parameters committee of the American College of G. American College of gastroenterology guideline on the management of *Helicobacter pylori* infection. *Am J Gastroenterol.* 2007;102(8):1808–25. doi:10.1111/j.1572-0241.2007.01393.x.
 54. Megraud F, Lamouliatte H. Review article: the treatment of refractory *Helicobacter pylori* infection. *Aliment Pharmacol Ther.* 2003;17(11):1333–43.
 55. Zhang W, Chen Q, Liang X, Liu W, Xiao S, Graham DY, et al. Bismuth, lansoprazole, amoxicillin and metronidazole or clarithromycin as first-line *Helicobacter pylori* therapy. *Gut.* 2015;64(11):1715–20. doi:10.1136/gutjnl-2015-309900.
 56. Qureshi NN, Gallaher B, Schiller NL. Evolution of amoxicillin resistance of *Helicobacter pylori* in vitro: characterization of resistance mechanisms. *Microb Drug Resist.* 2014;20(6):509–16. doi:10.1089/mdr.2014.0019.
 57. Fischbach L, Evans EL. Meta-analysis: the effect of antibiotic resistance status on the efficacy of triple and quadruple first-line therapies for *Helicobacter pylori*. *Aliment Pharmacol Ther.* 2007;26(3):343–57. doi:10.1111/j.1365-2036.2007.03386.x.
 58. Cao Z, Chen Q, Zhang W, Liang X, Liao J, Liu W, et al. Fourteen-day optimized levofloxacin-based therapy versus classical quadruple therapy for *Helicobacter pylori* treatment failures: a randomized clinical trial. *Scand J Gastroenterol.* 2015;50(10):1185–90. doi:10.3109/00365521.2015.1037345.
 59. Gisbert JP, Romano M, Gravina AG, Solis-Munoz P, Bermejo F, Molina-Infante J, et al. *Helicobacter pylori* second-line rescue therapy with levofloxacin- and bismuth-containing quadruple therapy, after failure of standard triple or non-bismuth quadruple treatments. *Aliment Pharmacol Ther.* 2015;41(8):768–75. doi:10.1111/apt.13128.
 60. Liao J, Zheng Q, Liang X, Zhang W, Sun Q, Liu W, et al. Effect of fluoroquinolone resistance on 14-day levofloxacin triple and triple plus bismuth quadruple therapy. *Helicobacter.* 2013;18(5):373–7. doi:10.1111/hel.12052.
 61. Sun Q, Liang X, Zheng Q, Liu W, Xiao S, Gu W, et al. High efficacy of 14-day triple therapy-based, bismuth-containing quadruple therapy for initial *Helicobacter pylori* eradication. *Helicobacter.* 2010;15(3):233–8. doi:10.1111/j.1523-5378.2010.00758.x.
 62. Ge R, Chen Z, Zhou Q. The actions of bismuth in the treatment of *Helicobacter pylori* infections: an update. *Metallomics.* 2012;4(3):239–43. doi:10.1039/c2mt00180b.
 63. Lambert JR, Midolo P. The actions of bismuth in the treatment of *Helicobacter pylori* infection. *Aliment Pharmacol Ther.* 1997;11 Suppl 1:27–33.
 64. Thomas F, Bialek B, Hensel R. Medical use of bismuth: the two sides of the coin. *Clin Toxicol.* 2012;S3(004):1–5. doi:10.4172/2161-0495.
 65. Lambert JR, Borromeo J, Eaves ER, Hansky J, Korman MG. Efficacy of different dosage regimens of bismuth in eradicating *Campylobacter pylori*. *Gastroenterology.* 1988;94:A248.
 66. Marshall BJ, Valenzuela JE, McCallum RW, Dooley CP, Guerrant RL, Cohen H, et al. Bismuth subsalicylate suppression of *Helicobacter pylori* in nonulcer dyspepsia: a double-blind placebo-controlled trial. *Dig Dis Sci.* 1993;38(9):1674–80.
 67. McNulty CA. Bismuth subsalicylate in the treatment of gastritis due to *Campylobacter pylori*. *Rev Infect Dis.* 1990;12 Suppl 1: S94–8.
 68. Phillips RH, Whitehead MW, Lacey S, Champion M, Thompson RP, Powell JJ. Solubility, absorption, and anti-*Helicobacter pylori* activity of bismuth subnitrate and colloidal bismuth subcitrate: in vitro data do not predict in vivo efficacy. *Helicobacter.* 2000;5(3):176–82.
 69. Armstrong JA, Wee SH, Goodwin CS, Wilson DH. Response of *Campylobacter pyloridis* to antibiotics, bismuth and an acid-reducing agent in vitro—an ultrastructural study. *J Med Microbiol.* 1987;24(4):343–50. doi:10.1099/00222615-24-4-343.
 70. Marshall BJ, Armstrong JA, Francis GJ, Nokes NT, Wee SH. Antibacterial action of bismuth in relation to *Campylobacter pyloridis* colonization and gastritis. *Digestion.* 1987;37 Suppl 2: 16–30.
 71. Marcus EA, Sachs G, Scott DR. Colloidal bismuth subcitrate impedes proton entry into *Helicobacter pylori* and increases the efficacy of growth-dependent antibiotics. *Aliment Pharmacol Ther.* 2015. doi:10.1111/apt.13346.
 72. Just PM. Overview of the fluoroquinolone antibiotics. *Pharmacotherapy.* 1993;13(2 Pt 2):4S–17S.
 73. Cattoir V, Nectoux J, Lascols C, Deforges L, Delchier JC, Megraud F, et al. Update on fluoroquinolone resistance in

- Helicobacter pylori*: new mutations leading to resistance and first description of a gyrA polymorphism associated with hypersusceptibility. Int J Antimicrob Agents. 2007;29(4):389–96. doi:10.1016/j.ijantimicag.2006.11.007.
74. Moore RA, Beckthold B, Wong S, Kureishi A, Bryan LE. Nucleotide sequence of the gyrA gene and characterization of ciprofloxacin-resistant mutants of *Helicobacter pylori*. Antimicrob Agents Chemother. 1995;39(1):107–11.
 75. Chuah SK, Tai WC, Hsu PI, Wu DC, Wu KL, Kuo CM, et al. The efficacy of second-line anti-*Helicobacter pylori* therapy using an extended 14-day levofloxacin/amoxicillin/proton-pump inhibitor treatment—a pilot study. Helicobacter. 2012;17(5):374–81. doi:10.1111/j.1523-5378.2012.00960.x.
 76. Thung I, Aramin H, Vavinskaya V, Gupta S, Park JY, Crowe SE, et al. Review article: the global emergence of *Helicobacter pylori* antibiotic resistance. Aliment Pharmacol Ther. 2016;43(4):514–33. doi:10.1111/apt.13497. **Provides a comprehensive overview of antibiotic resistance mechanisms, how to test for antibiotic resistance, and how to target therapy based on these results.**
 77. Gerrits MM, de Zoete MR, Arents NL, Kuipers EJ, Kusters JG. 16S rRNA mutation-mediated tetracycline resistance in *Helicobacter pylori*. Antimicrob Agents Chemother. 2002;46(9):2996–3000.
 78. Chi CH, Lin CY, Sheu BS, Yang HB, Huang AH, Wu JJ. Quadruple therapy containing amoxicillin and tetracycline is an effective regimen to rescue failed triple therapy by overcoming the antimicrobial resistance of *Helicobacter pylori*. Aliment Pharmacol Ther. 2003;18(3):347–53.
 79. Delchier JC, Malfertheiner P, Thieroff-Ekerdt R. Use of a combination formulation of bismuth, metronidazole and tetracycline with omeprazole as a rescue therapy for eradication of *Helicobacter pylori*. Aliment Pharmacol Ther. 2014;40(2):171–7. doi:10.1111/apt.12808.
 80. Laine L, Hunt R, El-Zimaity H, Nguyen B, Osato M, Spenard J. Bismuth-based quadruple therapy using a single capsule of bismuth biscalcitate, metronidazole, and tetracycline given with omeprazole versus omeprazole, amoxicillin, and clarithromycin for eradication of *Helicobacter pylori* in duodenal ulcer patients: a prospective, randomized, multicenter, North American trial. Am J Gastroenterol. 2003;98(3):562–7.
 81. Malfertheiner P, Bazzoli F, Delchier JC, Celinski K, Giguere M, Riviere M, et al. *Helicobacter pylori* eradication with a capsule containing bismuth subcitrate potassium, metronidazole, and tetracycline given with omeprazole versus clarithromycin-based triple therapy: a randomised, open-label, non-inferiority, phase 3 trial. Lancet. 2011;377(9769):905–13. doi:10.1016/S0140-6736(11)60020-2.
 82. O'Morain C, Borody T, Farley A, De Boer WA, Dallaire C, Schuman R, et al. Efficacy and safety of single-triple capsules of bismuth biscalcitate, metronidazole and tetracycline, given with omeprazole, for the eradication of *Helicobacter pylori*: an international multicentre study. Aliment Pharmacol Ther. 2003;17(3):415–20.
 83. Muller N, Amiot A, Le Thuaut A, Bastuji-Garin S, Deforges L, Delchier JC. Rescue therapy with bismuth-containing quadruple therapy in patients infected with metronidazole-resistant *Helicobacter pylori* strains. Clin Res Hepatol Gastroenterol. 2016. doi:10.1016/j.clinre.2015.12.012.
 84. Heep M, Beck D, Bayerdorffer E, Lehn N. Rifampin and rifabutin resistance mechanism in *Helicobacter pylori*. Antimicrob Agents Chemother. 1999;43(6):1497–9.
 85. Heep M, Rieger U, Beck D, Lehn N. Mutations in the beginning of the rpoB gene can induce resistance to rifamycins in both *Helicobacter pylori* and *Mycobacterium tuberculosis*. Antimicrob Agents Chemother. 2000;44(4):1075–7.
 86. Borody TJ, Pang G, Wettstein AR, Clancy R, Herdman K, Surace R, et al. Efficacy and safety of rifabutin-containing 'rescue therapy' for resistant *Helicobacter pylori* infection. Aliment Pharmacol Ther. 2006;23(4):481–8. doi:10.1111/j.1365-2036.2006.02793.x.
 87. Lim HC, Lee YJ, An B, Lee SW, Lee YC, Moon BS. Rifabutin-based high-dose proton-pump inhibitor and amoxicillin triple regimen as the rescue treatment for *Helicobacter pylori*. Helicobacter. 2014;19(6):455–61. doi:10.1111/hel.12147.
 88. Gisbert JP, Calvet X. Review article: rifabutin in the treatment of refractory *Helicobacter pylori* infection. Aliment Pharmacol Ther. 2012;35(2):209–21. doi:10.1111/j.1365-2036.2011.04937.x.
 89. Romano M, Cuomo A, Gravina AG, Miranda A, Iovene MR, Tiso A, et al. Empirical levofloxacin-containing versus clarithromycin-containing sequential therapy for *Helicobacter pylori* eradication: a randomised trial. Gut. 2010;59(11):1465–70. doi:10.1136/gut.2010.215350.
 90. Zullo A, Hassan C, Morini S, De Francesco V, Ierardi E, Panella C, et al. Sequential therapy for *H. pylori*: an 'aberrant' therapy ready for general use. Dig Liver Dis. 2004;36(12):852–3. author reply 3.
 91. Liou JM, Chen CC, Chen MJ, Chen CC, Chang CY, Fang YJ, et al. Sequential versus triple therapy for the first-line treatment of *Helicobacter pylori*: a multicentre, open-label, randomised trial. Lancet. 2013;381(9862):205–13. doi:10.1016/S0140-6736(12)61579-7.
 92. Gisbert JP, Calvet X, O'Connor A, Megraud F, O'Morain CA. Sequential therapy for *Helicobacter pylori* eradication: a critical review. J Clin Gastroenterol. 2010;44(5):313–25. doi:10.1097/MCG.0b013e3181c8a1a3.
 93. Liou JM, Chen CC, Lee YC, Chang CY, Wu JY, Bair MJ, et al. Systematic review with meta-analysis: 10- or 14-day sequential therapy vs. 14-day triple therapy in the first line treatment of *Helicobacter pylori* infection. Aliment Pharmacol Ther. 2016;43(4):470–81. doi:10.1111/apt.13495.
 94. Graham DY, Shiotani A. Which therapy for *Helicobacter pylori* infection? Gastroenterology. 2012;143(1):10–2. doi:10.1053/j.gastro.2012.05.012.
 95. Essa AS, Kramer JR, Graham DY, Treiber G. Meta-analysis: four-drug, three-antibiotic, non-bismuth-containing "concomitant therapy" versus triple therapy for *Helicobacter pylori* eradication. Helicobacter. 2009;14(2):109–18. doi:10.1111/j.1523-5378.2009.00671.x.
 96. Georgopoulos S, Papastergiou V, Xirouchakis E, Laoudi F, Lisgos P, Spiliadi C, et al. Nonbismuth quadruple "concomitant" therapy versus standard triple therapy, both of the duration of 10 days, for first-line *H. pylori* eradication: a randomized trial. J Clin Gastroenterol. 2013;47(3):228–32. doi:10.1097/MCG.0b013e31826015b0.
 97. Gisbert JP, Calvet X. Update on non-bismuth quadruple (concomitant) therapy for eradication of *Helicobacter pylori*. Clin Exp Gastroenterol. 2012;5:23–34. doi:10.2147/CEG.S25419.
 98. Graham DY, Lee YC, Wu MS. Rational *Helicobacter pylori* therapy: evidence-based medicine rather than medicine-based evidence. Clin Gastroenterol Hepatol. 2014;12(2):177–86 e3. doi:10.1016/j.cgh.2013.05.028. Discussion e12-3.
 99. Hsu PI, Wu DC, Wu JY, Graham DY. Modified sequential *Helicobacter pylori* therapy: proton pump inhibitor and amoxicillin for 14 days with clarithromycin and metronidazole added as a quadruple (hybrid) therapy for the final 7 days. Helicobacter. 2011;16(2):139–45. doi:10.1111/j.1523-5378.2011.00828.x.
 100. Hsu PI, Lin PC, Graham DY. Hybrid therapy for *Helicobacter pylori* infection: a systemic review and meta-analysis. World J Gastroenterol. 2015;21(45):12954–62. doi:10.3748/wjg.v21.i45.12954.

101. Wang B, Wang YH, Lv ZF, Xiong HF, Wang H, Yang Y, et al. Review: efficacy and safety of hybrid therapy for *Helicobacter pylori* infection: a systematic review and meta-analysis. *Helicobacter*. 2015;20(2):79–88. doi:10.1111/hel.12180.
102. Glupczynski Y, Megraud F, Lopez-Brea M, Andersen LP. European multicentre survey of in vitro antimicrobial resistance in *Helicobacter pylori*. *Eur J Clin Microbiol Infect Dis*. 2001;20(11):820–3.
103. Heep M, Kist M, Strobel S, Beck D, Lehn N. Secondary resistance among 554 isolates of *Helicobacter pylori* after failure of therapy. *Eur J Clin Microbiol Infect Dis*. 2000;19(7):538–41.
104. Meyer JM, Silliman NP, Wang W, Siepmann NY, Sugg JE, Morris D, et al. Risk factors for *Helicobacter pylori* resistance in the United States: the surveillance of *H. pylori* antimicrobial resistance partnership (SHARP) study, 1993–1999. *Ann Intern Med*. 2002;136(1):13–24.
105. Graham KS, Malaty H, el-Zimaity HM, Genta RM, Cole RA, al-Assi MT, et al. Variability with omeprazole-amoxicillin combinations for treatment of *Helicobacter pylori* infection. *Am J Gastroenterol*. 1995;90(9):1415–8.
106. Sjostedt S, Sagar M, Lindberg G, Wikstrom B, Nord CE, Seensalu R. Prolonged and profound acid inhibition is crucial in *Helicobacter pylori* treatment with a proton pump inhibitor combined with amoxicillin. *Scand J Gastroenterol*. 1998;33(1):39–43.
107. Yang JC, Wang HL, Chen HD, Shun CT, Lin BR, Lin CJ, et al. Role of omeprazole dosage and cytochrome P450 2C19 genotype in patients receiving omeprazole-amoxicillin dual therapy for *Helicobacter pylori* eradication. *Pharmacotherapy*. 2011;31(3):227–38. doi:10.1592/phco.31.3.227.
108. MacGowan AP, Bowker KE. Continuous infusion of beta-lactam antibiotics. *Clin Pharmacokinet*. 1998;35(5):391–402.
109. Midolo PD, Turnidge JD, Munckhof WJ. Is bactericidal activity of amoxicillin against *Helicobacter pylori* concentration dependent? *Antimicrob Agents Chemother*. 1996;40(5):1327–8.
110. Yang JC, Lin CJ, Wang HL, Chen JD, Kao JY, Shun CT, et al. High-dose dual therapy is superior to standard first-line or rescue therapy for *Helicobacter pylori* infection. *Clin Gastroenterol Hepatol*. 2015;13(5):895–905 e5. doi:10.1016/j.cgh.2014.10.036. **Offers promise for the future of therapy for *H. pylori*, with an option for decreased antibiotic use, although results are not currently generalizable worldwide.**
111. Sakurai Y, Mori Y, Okamoto H, Nishimura A, Komura E, Araki T, et al. Acid-inhibitory effects of vonoprazan 20 mg compared with esomeprazole 20 mg or rabeprazole 10 mg in healthy adult male subjects—a randomised open-label cross-over study. *Aliment Pharmacol Ther*. 2015. doi:10.1111/apt.13325.
112. Inaba T, Iwamuro M, Toyokawa T, Okada H. Letter: promising results of *Helicobacter pylori* eradication with vonoprazan-based triple therapy after failure of proton pump inhibitor-based triple therapy. *Aliment Pharmacol Ther*. 2016;43(1):179–80. doi:10.1111/apt.13462.
113. Murakami KSY, Shiino M, Funao N, Nishimura A, Asaka M. A phase 3, double-blind study of a triple therapy with TAK-438, amoxicillin, and clarithromycin as first line eradication of *H. pylori* and a triple therapy with TAK-438, amoxicillin, and metronidazole as second line eradication of *H. pylori*. *Gastroenterology*. 2014;146 Suppl 5:740.
114. Puscas I. Treatment of gastroduodenal ulcers with carbonic anhydrase inhibitors. *Ann N Y Acad Sci*. 1984;429:587–91.
115. Buzas GM. Carbonic anhydrase, acetazolamide and *Helicobacter pylori* infection. *Helicobacter*. 2005;10(5):444. doi:10.1111/j.1523-5378.2005.00353.x.
116. Shahidzadeh R, Opekun A, Shiotani A, Graham DY. Effect of the carbonic anhydrase inhibitor, acetazolamide, on *Helicobacter pylori* infection in vivo: a pilot study. *Helicobacter*. 2005;10(2):136–8. doi:10.1111/j.1523-5378.2005.00306.x.